Lebrikizumab(一种抗IL-13单克隆抗体)在中重度特应性皮炎且外用糖皮质激素控制不佳成人中的疗效与安全性:一项随机、安慰剂对照II期试验(TREBLE)
这项随机、安慰剂对照、双盲II期试验纳入209例接受每日两次外用糖皮质激素(TCS)的中重度特应性皮炎成人患者,比较lebrikizumab不同方案与安慰剂的疗效。第12周时,lebrikizumab 125 mg每4周组达到EASI-50的患者比例显著高于安慰剂每4周组(82.4% vs 62.3%,P=0.026),单次给药组与安慰剂相比无统计学显著改善;不良事件发生率两组相似(所有lebrikizumab组66.7% vs 安慰剂组66.0%),多为轻中度。
要点
- lebrikizumab 125 mg每4周联合TCS较安慰剂显著提高第12周EASI-50达标率(82.4% vs 62.3%,P=0.026)。
- lebrikizumab单次给药(125 mg或250 mg)在EASI-50上未显示优于安慰剂的统计学显著改善。
- 不良事件发生率所有lebrikizumab组66.7% vs 安慰剂组66.0%,大多为轻中度。
核心结论
- 与TCS联合使用时,lebrikizumab 125 mg每4周给药可使中重度特应性皮炎患者获得显著改善且耐受性良好。
研究设计与样本
- 随机、安慰剂对照、双盲II期研究;中重度特应性皮炎成人需每日两次使用TCS,经2周TCS导入期后按1:1:1:1随机分为lebrikizumab 125 mg单次剂量、lebrikizumab 250 mg单次剂量、lebrikizumab 125 mg每4周共12周或安慰剂每4周共12周。
- 共209例患者接受了研究药物。
主要发现
- 第12周时,lebrikizumab 125 mg每4周组达到EASI-50的患者比例为82.4%,显著高于安慰剂每4周组的62.3%(P=0.026)。
- 接受lebrikizumab单次剂量的患者在EASI-50上较安慰剂无统计学显著改善。
- 不良事件发生率各组相似(所有lebrikizumab组66.7% vs 安慰剂组66.0%),且大多为轻度或中度。
关键数值与推荐
- 主要终点为第12周达到湿疹面积和严重度指数(EASI)-50的患者百分比。
- 第12周EASI-50:lebrikizumab 125 mg每4周组82.4% vs 安慰剂每4周组62.3%(P=0.026)。
- 不良事件:所有lebrikizumab组66.7% vs 安慰剂组66.0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 方案规定的每日两次TCS治疗限制了对lebrikizumab单药疗效的理解。
- 研究持续时间短,无法评估长期疗效或安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interleukin (IL)-13 plays a key role in type 2 inflammation and is an emerging pathogenic mediator in atopic dermatitis (AD). OBJECTIVE: We investigated the efficacy and safety of lebrikizumab, an IL-13 monoclonal antibody, as an add-on to topical corticosteroid (TCS) treatment. METHODS: A randomized, placebo-controlled, double-blind, phase 2 study. Adults with moderate-to-severe AD were required to use TCS twice daily and then randomized (1:1:1:1) to lebrikizumab 125 mg single dose, lebrikizumab 250 mg single dose, lebrikizumab 125 mg every 4 weeks for 12 weeks, or placebo every 4 weeks for 12 weeks, after a 2-week TCS run-in. The primary endpoint was percentage of patients achieving Eczema Area and Severity Index (EASI)-50 at week 12. RESULTS: In total, 209 patients received the study drug. At week 12, significantly more patients achieved EASI-50 with lebrikizumab 125 mg every 4 weeks (82.4%; P = .026) than placebo every 4 weeks (62.3%); patients receiving a single dose of lebrikizumab showed no statistically significant improvements in EASI-50 compared with placebo. Adverse events were similar between groups (66.7% all lebrikizumab vs 66.0% placebo) and mostly mild or moderate. LIMITATIONS: Protocol-mandated twice daily TCS treatment limits our understanding of the efficacy of lebrikizumab as a monotherapy. The short study duration did not enable long-term efficacy or safety evaluations. CONCLUSION: When combined with TCS, lebrikizumab 125 mg taken every 4 weeks led to a significant improvement and was well tolerated in patients with moderate-to-severe AD.
引用
- Simpson EL, Flohr C, Eichenfield LF, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018. PMID: 29353026. doi:10.1016/j.jaad.2018.01.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。